Insmed Inc insider trading
Every open-market purchase and sale by Insmed Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Insmed Inc’s insiders pay?
From March 24, 2011 to September 11, 2026, 24 insiders reported 32 open-market purchases and 138 sales not made under a pre-set plan in Insmed Inc. Twelve months after each purchase was reported, the shares were +5.9% against the S&P 500 on average (median −6.8%), over 30 purchases with a full year of prices; 40% beat the index. After sales, the shares moved +33.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 25, 2011 into $47,921 by November 2, 2026, +10.6% a year. It held shares 73% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $59,392 (+12.1% a year), and held throughout $75,574 (+13.9%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO | 7 | +70.8% (7) | 57% | 17 | +37.5% (13) | June 5, 2026 |
| Smith Michael Alexander | Chief Legal Officer | 0 | — | — | 20 | +57.5% (16) | June 5, 2026 |
| Adsett Roger | Chief Operating Officer | 1 | −6.8% (1) | 0% | 18 | +30.6% (13) | August 12, 2026 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer | 0 | — | — | 18 | +28.0% (17) | November 14, 2025 |
| Sharoky Melvin Md | Director | 8 | −3.9% (7) | 57% | 8 | −40.0% (6) | August 19, 2026 |
| Bonstein Sara | Chief Financial Officer | 0 | — | — | 14 | +53.1% (10) | June 5, 2026 |
| Flammer Martina M.D. | Chief Medical Officer | 0 | — | — | 11 | +37.1% (11) | June 4, 2025 |
| Fmr LLC | 10% owner | 0 | — | — | 9 | +28.0% (9) | July 23, 2013 |
| Wise John Drayton | Chief Commercial Officer | 0 | — | — | 8 | +77.3% (8) | February 7, 2025 |
| Engelsen Steinar J | Director | 4 | −34.3% (4) | 0% | 0 | — | November 3, 2021 |
| Soriano John | Chief Compliance Officer | 0 | — | — | 4 | −37.9% (4) | September 9, 2021 |
| Hayden Donald J Jr | Director | 2 | −52.5% (2) | 0% | 1 | −59.3% (1) | September 3, 2015 |
| Pellizzari Christine A | Chief Legal Officer | 2 | +76.4% (2) | 100% | 1 | −35.0% (1) | November 5, 2020 |
| Anderson Elizabeth M | Director | 0 | — | — | 2 | — | November 26, 2025 |
| Brennan David R | Director | 1 | −27.4% (1) | 0% | 1 | — | September 11, 2026 |
| Drechsler Andrew T | Chief Financial Officer | 0 | — | — | 2 | +64.1% (2) | March 3, 2017 |
| Lee Leo | Director | 1 | +13.8% (1) | 100% | 1 | — | November 18, 2025 |
| Whitcomb Randall W | Director | 2 | −49.9% (2) | 0% | 0 | — | March 29, 2011 |
| Whitten Timothy | President & CEO | 2 | −57.3% (1) | 0% | 0 | — | June 4, 2012 |
| Desjardins Clarissa | Director | 1 | +26.5% (1) | 100% | 0 | — | May 22, 2025 |
| Goll John | Chief Accounting Officer | 0 | — | — | 1 | +70.2% (1) | November 20, 2019 |
| Gupta Renu | EVP & Chief Medical Officer | 1 | −50.4% (1) | 0% | 0 | — | March 28, 2011 |
| Potter Myrtle S | Director | 0 | — | — | 1 | +101.3% (1) | December 15, 2016 |
| Quigley Mark | Vice President, Quality | 0 | — | — | 1 | −51.3% (1) | May 13, 2015 |
When several insiders traded Insmed Inc
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Insmed Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −3.8% against the index. After 9 selling crowds, +27.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| January 31, 2025 | 3 selling | 0.0% | +39.8% | +89.3% |
| May 31, 2024 | 7 selling | +31.7% | +21.6% | +19.4% |
| January 31, 2024 | 7 selling | −11.9% | +157.8% | +154.8% |
| May 31, 2023 | 7 selling | +7.7% | +22.3% | +161.2% |
| January 31, 2023 | 7 selling | −12.0% | −10.5% | +10.3% |
| May 31, 2022 | 6 selling | +30.1% | −0.3% | −1.7% |
| January 31, 2022 | 6 selling | +6.6% | +1.1% | +2.5% |
| November 30, 2021 | 2 buying | −10.1% | −25.4% | −23.7% |
| September 30, 2020 | 3 selling | −5.8% | −10.3% | −44.3% |
| November 30, 2018 | 4 buying | +62.6% | +29.2% | +13.7% |
| December 30, 2016 | 3 selling | +25.8% | +21.9% | +122.8% |
| March 31, 2011 | 4 buying | +77.6% | −15.1% | −54.7% |